Gilead connects its diverse therapeutic areas—virology, oncology, and immunology—through a unified scientific principle. The immune system is the common thread: it must be activated to fight viruses and cancer but dampened in autoimmune diseases. This allows platform technologies like CAR-T to be leveraged across all three areas.
A key lesson from Gilead's dominance in HIV is the principle of rapid iteration. This means quickly moving from one successful product to the next, even if it makes the previous one obsolete. This mindset extends to R&D, where the company readily exchanges internal programs for superior external innovation opportunities.
Gilead has tightened its criteria for advancing projects, demanding a deep mechanistic understanding before committing significant resources. This involves validating the target, understanding its biological impact preclinically, and identifying biomarkers—moving beyond just a promising hypothesis to a de-risked scientific thesis.
Gilead's acquisition strategy is not monolithic. It differentiates between acquiring foundational, long-duration platforms (like Kite's CAR-T) that kickstart a whole new area of R&D, and acquiring differentiated assets (like Arcelix's BCMA CAR-T) that strengthen an existing therapeutic area with a potentially transformative molecule.
To avoid chasing hype, Gilead's business development filter prioritizes opportunities with transformative potential, specifically the possibility of a cure (like in Hepatitis C or with CAR-T). This constrains them from pursuing assets that offer only symptom control or convenience, even if they are favored by investors.
While acknowledging AI's current impact on productivity (e.g., doubling trial recruitment speed), Gilead views its ultimate transformative potential in supporting complex strategic decisions. This includes using AI to synthesize disparate data (genomic, literature, RWE) to identify the optimal disease indications for a new drug target.